Extracellular Vesicles: Translational Agenda Questions for Three Protozoan Parasites.
Plasmodium falciparum
Trypanosoma cruzi
Chagas disease
Leishmania spp.
extracellular vesicles
future studies
leishmaniasis
malaria
translational potential
Journal
Traffic (Copenhagen, Denmark)
ISSN: 1600-0854
Titre abrégé: Traffic
Pays: England
ID NLM: 100939340
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
02
04
2024
received:
16
10
2023
accepted:
03
04
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
ppublish
Résumé
The protozoan parasites Plasmodium falciparum, Leishmania spp. and Trypanosoma cruzi continue to exert a significant toll on the disease landscape of the human population in sub-Saharan Africa and Latin America. Control measures have helped reduce the burden of their respective diseases-malaria, leishmaniasis and Chagas disease-in endemic regions. However, the need for new drugs, innovative vaccination strategies and molecular markers of disease severity and outcomes has emerged because of developing antimicrobial drug resistance, comparatively inadequate or absent vaccines, and a lack of trustworthy markers of morbid outcomes. Extracellular vesicles (EVs) have been widely reported to play a role in the biology and pathogenicity of P. falciparum, Leishmania spp. and T. cruzi ever since they were discovered. EVs are secreted by a yet to be fully understood mechanism in protozoans into the extracellular milieu and carry a cargo of diverse molecules that reflect the originator cell's metabolic state. Although our understanding of the biogenesis and function of EVs continues to deepen, the question of how EVs in P. falciparum, Leishmania spp. and T. cruzi can serve as targets for a translational agenda into clinical and public health interventions is yet to be fully explored. Here, as a consortium of protozoan researchers, we outline a plan for future researchers and pose three questions to direct an EV's translational agenda in P. falciparum, Leishmania spp. and T. cruzi. We opine that in the long term, executing this blueprint will help bridge the current unmet needs of these medically important protozoan diseases in sub-Saharan Africa and Latin America.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12935Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
World Malaria Report 2021. (Geneva: World Health Organization), 2021. Licence: CC BY‐NC‐SA 3.0 IGO.
WHO, “Neglected Tropical Diseases,” 2022 https://www.who.int/health‐topics/neglected‐tropical‐diseases#tab=tab_1.
F. A. Siddiqui, X. Liang, and L. Cui, “Plasmodium falciparum Resistance to ACTs: Emergence, Mechanisms, and Outlook,” International Journal for Parasitology: Drugs and Drug Resistance 16 (2021): 102–118.
A. Ponte‐Sucre, F. Gamarro, J. C. Dujardin, et al., “Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century Challenge,” PLoS Neglected Tropical Diseases 11 (2017): e0006052.
M. Laureano de Souza, T. Lapierre, V. de Lima, et al., “Molecular Targets for Chagas Disease: Validation, Challenges and Lead Compounds for Widely Exploited Targets,” Expert Opinion on Therapeutic Targets 27 (2023): 911–925.
M. Olivier and C. Fernandez‐Prada, “Leishmania and Its Exosomal Pathway: A Novel Direction for Vaccine Development,” Future Microbiology 14 (2019): 559–561.
K. T. J. Dzi, “Issues Related to the Approval of the R21/Matrix‐M Malaria Vaccine for Use in Nigeria and Ghana,” Frontiers in Public Health 11 (2023): 1237011.
World Malaria Report 2023. (Geneva: World Health Organization), 2023. Licence: CC BY‐NC‐SA 3.0 IGO.
Y. Couch, E. I. Buzàs, D. Di Vizio, et al., “A Brief History of Nearly EV‐Erything—The Rise and Rise of Extracellular Vesicles,” Journal of Extracellular Vesicles 10 (2021): e12144.
C. Fernandez‐Becerra, P. Xander, D. Alfandari, et al., “Guidelines for the Purification and Characterization of Extracellular Vesicles of Parasites,” Journal of Extracellular Biology 2 (2023): e117.
A. C. Torrecilhas, R. P. Soares, S. Schenkman, C. Fernández‐Prada, and M. Olivier, “Extracellular Vesicles in Trypanosomatids: Host Cell Communication,” Frontiers in Cellular and Infection Microbiology 10 (2020): 602502.
N. Regev‐Rudzki, D. W. Wilson, T. G. Carvalho, et al., “Cell‐Cell Communication Between Malaria‐Infected Red Blood Cells via Exosome‐Like Vesicles,” Cell 153 (2013): 1120–1133.
I. S. Cheng, B. C. Sealy, N. Tiberti, and V. Combes, “Extracellular Vesicles, From Pathogenesis to Biomarkers: The Case for Cerebral Malaria,” Vessel Plus 4 (2020): 17.
K. Z. Tandoh, C. M. Morang'a, M. Wilson, N. B. Quashie, and N. O. Duah‐Quashie, “Malaria Artemisinin Resistance: An Extracellular Vesicles Export Hypothesis,” Trends in Parasitology 38 (2022): 614–617.
K. Z. Tandoh, M. D. Wilson, N. B. Quashie, and N. O. Duah‐Quashie, “Implicating Extracellular Vesicles in Plasmodium falciparum Artemisinin Resistance Development,” Traffic 22 (2021): 194–200.
Y. Avalos‐Padilla, V. N. Georgiev, E. Lantero, et al., “The ESCRT‐III Machinery Participates in the Production of Extracellular Vesicles and Protein Export During Plasmodium falciparum Infection,” PLoS Pathogens 17 (2021): e1009455.
P. Langfelder and S. Horvath, “WGCNA: An R Package for Weighted Correlation Network Analysis,” BMC Bioinformatics 9 (2008): 559.
K. Z. Tandoh, O. C. Hagan, M. D. Wilson, N. B. Quashie, and N. O. Duah‐Quashie, “Transcriptome‐Module Phenotype Association Study Implicates Extracellular Vesicles Biogenesis in Plasmodium falciparum Artemisinin Resistance,” Frontiers in Cellular and Infection Microbiology 12 (2022): 886728.
A. Cruz Camacho, D. Alfandari, E. Kozela, and N. Regev‐Rudzki, “Biogenesis of Extracellular Vesicles in Protozoan Parasites: The ESCRT Complex in the Trafficking Fast Lane?” PLoS Pathogens 19 (2023): e1011140.
M. Kioko, A. Pance, S. Mwangi, et al., “Extracellular Vesicles Could Be a Putative Posttranscriptional Regulatory Mechanism That Shapes Intracellular RNA Levels in Plasmodium falciparum,” Nature Communications 14 (2023): 6447.
C. Fernández‐Prada, N. Douanne, A. Minguez‐Menendez, et al., “Repurposed Molecules: A New Hope in Tackling Neglected Infectious Diseases,” in In Silico Drug Design, (Amsterdam: Elsevier, 2019).
P. Leprohon, C. Fernandez‐Prada, É. Gazanion, R. Monte‐Neto, and M. Ouellette, “Drug Resistance Analysis by Next Generation Sequencing in Leishmania,” International Journal for Parasitology: Drugs and Drug Resistance 5 (2015): 26–35.
J. M. Ubeda, F. Raymond, A. Mukherjee, et al., “Genome‐Wide Stochastic Adaptive DNA Amplification at Direct and Inverted DNA Repeats in the Parasite Leishmania,” PLoS Biology 12 (2014): e1001868.
N. Douanne, G. Dong, A. Amin, et al., “Leishmania Parasites Exchange Drug‐Resistance Genes Through Extracellular Vesicles,” Cell Reports 40 (2022): 111121.
N. Douanne, G. Dong, M. Douanne, M. Olivier, and C. Fernandez‐Prada, “Unravelling the Proteomic Signature of Extracellular Vesicles Released by Drug‐Resistant Leishmania infantum Parasites,” PLoS Neglected Tropical Diseases 14 (2020): e0008439.
V. D. Atayde, A. da Silva Lira Filho, V. Chaparro, et al., “Exploitation of the Leishmania Exosomal Pathway by Leishmania RNA Virus 1,” Nature Microbiology 4 (2019): 714–723.
N. Cortes‐Serra, M. Gualdron‐Lopez, M. J. Pinazo, A. C. Torrecilhas, and C. Fernandez‐Becerra, “Extracellular Vesicles in Trypanosoma cruzi Infection: Immunomodulatory Effects and Future Perspectives as Potential Control Tools Against Chagas Disease,” Journal of Immunology Research 2022 (2022): 5230603.
W. Colli, “Trans‐Sialidase: A Unique Enzyme Activity Discovered in the Protozoan Trypanosoma cruzi,” The FASEB Journal 7 (1993): 1257–1264.
S. Schenkman, M. A. Ferguson, N. Heise, et al., “Mucin‐Like Glycoproteins Linked to the Membrane by Glycosylphosphatidylinositol Anchor Are the Major Acceptors of Sialic Acid in a Reaction Catalyzed by Trans‐Sialidase in Metacyclic Forms of Trypanosoma cruzi,” Molecular and Biochemical Parasitology 59 (1993): 293–303.
F. Urabe, N. Kosaka, K. Ito, T. Kimura, S. Egawa, and T. Ochiya, “Extracellular Vesicles as Biomarkers and Therapeutic Targets for Cancer,” American Journal of Physiology. Cell Physiology 318 (2020): C29–C39.
A. V. Ibarra‐Meneses, J. Moreno, and E. Carrillo, “New Strategies and Biomarkers for the Control of Visceral Leishmaniasis,” Trends in Parasitology 36 (2020): 29–38.
A. Rodriguez‐Cortes, A. Ojeda, O. Francino, L. Lopez‐Fuertes, M. Timon, and J. Alberola, “Leishmania Infection: Laboratory Diagnosing in the Absence of a “Gold Standard”,” The American Journal of Tropical Medicine and Hygiene 82 (2010): 251–256.
K. Kusakisako, R. Nakao, and K. Katakura, “Detection of Parasite‐Derived tRNA and rRNA Fragments in the Peripheral Blood of Mice Experimentally Infected With Leishmania donovani and Leishmania amazonensis Using Next‐Generation Sequencing Analysis,” Parasitology International 93 (2023): 102716.
S. Hendrickx, P. J. Guerin, G. Caljon, S. L. Croft, and L. Maes, “Evaluating Drug Resistance in Visceral Leishmaniasis: The Challenges,” Parasitology 145 (2018): 453–463.
M. A. Ballinas‐Verdugo, R. F. Jimenez‐Ortega, E. Martinez‐Martinez, et al., “Circulating miR‐146a as a Possible Candidate Biomarker in the Indeterminate Phase of Chagas Disease,” Biological Research 54 (2021): 21.
M. Alexander, R. Hu, M. C. Runtsch, et al., “Exosome‐Delivered MicroRNAs Modulate the Inflammatory Response to Endotoxin,” Nature Communications 6 (2015): 7321.
L. Qiu, J. Wang, M. Chen, F. Chen, and W. Tu, “Exosomal MicroRNA‐146a Derived From Mesenchymal Stem Cells Increases the Sensitivity of Ovarian Cancer Cells to Docetaxel and Taxane via a LAMC2‐Mediated PI3K/Akt Axis,” International Journal of Molecular Medicine 46 (2020): 609–620.
J. Yang, F. Malone, M. Go, et al., “Lipopolysaccharide‐Induced Exosomal miR‐146a Is Involved in Altered Expression of Alzheimer's Risk Genes via Suppression of TLR4 Signaling,” Journal of Molecular Neuroscience 71 (2021): 1245–1255.
M. L. Higuchi, J. T. Kawakami, R. N. Ikegami, et al., “Archaea Symbiont of T. cruzi Infection may Explain Heart Failure in Chagas Disease,” Frontiers in Cellular and Infection Microbiology 8 (2018): 412.
R. P. Madeira, L. M. Dal'Mas Romera, P. de Cássia Buck, C. Mady, B. M. Ianni, and A. C. Torrecilhas, “New Biomarker in Chagas Disease: Extracellular Vesicles Isolated From Peripheral Blood in Chronic Chagas Disease Patients Modulate the Human Immune Response,” Journal of Immunology Research 2021 (2021): 6650670.
A. Frimpong, K. A. Kusi, M. F. Ofori, and W. Ndifon, “Novel Strategies for Malaria Vaccine Design,” Frontiers in Immunology 9 (2018): 2769.
D. Alfandari, S. Cadury, M. I. Morandi, and N. Regev‐Rudzki, “Transforming Parasites Into Their Own Foes: Parasitic Extracellular Vesicles as a Vaccine Platform,” Trends in Parasitology 39 (2023): 913–928.
R. Velez and M. Gallego, “Commercially Approved Vaccines for Canine Leishmaniosis: A Review of Available Data on Their Safety and Efficacy,” Tropical Medicine & International Health 25 (2020): 540–557.
G. Castelli, F. Bruno, L. Saieva, et al., “Exosome Secretion by Leishmania infantum Modulate the Chemotactic Behavior and Cytokinic Expression Creating an Environment Permissive for Early Infection,” Experimental Parasitology 198 (2019): 39–45.
V. D. Atayde, H. Aslan, S. Townsend, K. Hassani, S. Kamhawi, and M. Olivier, “Exosome Secretion by the Parasitic Protozoan Leishmania Within the Sand Fly Midgut,” Cell Reports 13 (2015): 957–967.
A. da Silva Lira Filho, E. F. Fajardo, K. P. Chang, P. Clement, and M. Olivier, “Leishmania Exosomes/Extracellular Vesicles Containing GP63 Are Essential for Enhance Cutaneous Leishmaniasis Development Upon Co‐Inoculation of Leishmania amazonensis and Its Exosomes,” Frontiers in Cellular and Infection Microbiology 11 (2021): 709258.
R. P. Soares, P. Xander, A. O. Costa, et al., “Highlights of the Sao Paulo ISEV Workshop on Extracellular Vesicles in Cross‐Kingdom Communication,” Journal of Extracellular Vesicles 6 (2017): 1407213.
K. M. da Costa, L. M. da Fonseca, J. S. Dos Reis, et al., “Trypanosoma cruzi Trans‐Sialidase as a Potential Vaccine Target Against Chagas Disease,” Frontiers in Cellular and Infection Microbiology 11 (2021): 768450.
L. D. Caeiro, C. D. Alba‐Soto, M. Rizzi, et al., “The Protein Family TcTASV‐C Is a Novel Trypanosoma cruzi Virulence Factor Secreted in Extracellular Vesicles by Trypomastigotes and Highly Expressed in Bloodstream Forms,” PLoS Neglected Tropical Diseases 12 (2018): e0006475.
C. Serna, J. A. Lara, S. P. Rodrigues, A. F. Marques, I. C. Almeida, and R. A. Maldonado, “A Synthetic Peptide From Trypanosoma cruzi Mucin‐Like Associated Surface Protein as Candidate for a Vaccine Against Chagas Disease,” Vaccine 32 (2014): 3525–3532.
B. C. Gutierrez, M. E. Ancarola, I. Volpato‐Rossi, et al., “Extracellular Vesicles From Trypanosoma cruzi‐Dendritic Cell Interaction Show Modulatory Properties and Confer Resistance to Lethal Infection as a Cell‐Free Based Therapy Strategy,” Frontiers in Cellular and Infection Microbiology 12 (2022): 980817.